Literature DB >> 9177549

Effect of atenolol on nocturnal sleep and temperature in young men: reversal by pharmacological doses of melatonin.

C J Van Den Heuvel1, K J Reid, D Dawson.   

Abstract

To examine the physiological role of melatonin in sleep, nocturnal melatonin secretion was suppressed using 100 mg oral atenolol in two studies. In Study 1, nocturnal sleep was recorded in 8 young men over 4 nights. Subjects received atenolol on one of the last 2 nights and showed significantly increased total wake time (TWT) and wakefulness after sleep onset (WASO), as well as decreased REM sleep and slow-wave sleep (SWS). When melatonin (total 5 mg) was given after atenolol on the other night, the changes in TWT, WASO, REM, and SWS were reversed. In Study 2, sleep onset latencies (SOL) and core temperature (Tc) of 10 young men were measured for 3 nonconsecutive nights. In a cross-over design, atenolol given on one night significantly suppressed urinary 6-sulphatoxymelatonin (6s-aMT) production and increased hourly measures of Tc and SOL relative to baseline night values. Oral melatonin (3 mg), administered after atenolol, reversed the changes in Tc and SOL. These results suggest that endogenous melatonin may assist in the maintenance of normal sleep architecture (Study 1) and also increase nocturnal sleep propensity by hypothermic effects (Study 2).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177549     DOI: 10.1016/s0031-9384(96)00534-3

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  16 in total

Review 1.  Circadian system, sleep and endocrinology.

Authors:  Christopher J Morris; Daniel Aeschbach; Frank A J L Scheer
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

2.  Melatonin: an adjunctive treatment for cardiometabolic disease?

Authors:  Helen J Burgess
Journal:  Sleep       Date:  2012-10-01       Impact factor: 5.849

3.  Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.

Authors:  Frank A J L Scheer; Christopher J Morris; Joanna I Garcia; Carolina Smales; Erin E Kelly; Jenny Marks; Atul Malhotra; Steven A Shea
Journal:  Sleep       Date:  2012-10-01       Impact factor: 5.849

4.  Reduced sleep efficiency in cervical spinal cord injury; association with abolished night time melatonin secretion.

Authors:  F A J L Scheer; J M Zeitzer; N T Ayas; R Brown; C A Czeisler; S A Shea
Journal:  Spinal Cord       Date:  2006-02       Impact factor: 2.772

Review 5.  Sex differences in circadian timing systems: implications for disease.

Authors:  Matthew Bailey; Rae Silver
Journal:  Front Neuroendocrinol       Date:  2013-11-25       Impact factor: 8.606

6.  Altered sleep architecture and higher incidence of subsyndromal depression in low endogenous melatonin secretors.

Authors:  Shadab Ataur Rahman; Shai Marcu; Leonid Kayumov; Colin Michael Shapiro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-12-18       Impact factor: 5.270

Review 7.  Good night and good luck: norepinephrine in sleep pharmacology.

Authors:  Heather A Mitchell; David Weinshenker
Journal:  Biochem Pharmacol       Date:  2009-10-13       Impact factor: 5.858

Review 8.  Role of the melatonin system in the control of sleep: therapeutic implications.

Authors:  Seithikurippu R Pandi-Perumal; Venkatramanujan Srinivasan; D Warren Spence; Daniel P Cardinali
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 9.  Complementary and alternative medicine for sleep disturbances in older adults.

Authors:  Nalaka S Gooneratne
Journal:  Clin Geriatr Med       Date:  2008-02       Impact factor: 3.076

Review 10.  [Sleeping behaviour and headache attacks in cases of primary headache. Possible pathological mechanisms].

Authors:  A Straube; S Förderreuther
Journal:  Schmerz       Date:  2004-08       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.